ClinicalTrials.gg
CompletedNCT00657904Updated Jun 6, 2012

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

A Phase 3 interventional study of Bicalutamide and Placebo in Non-metastatic Prostate Cancer, sponsored by AstraZeneca. Completed at 85 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,618
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Enrollment
2nd of 54
3,618 · median 53
Started
1995
with 2 others
Phase 3
21 of 55
1 open now
Registered
25th of 55
by date
Lead sponsor
8 of 55
AstraZeneca

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 2nd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 1995, is one of 21 in phase 3, and was the 25th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

03

Conditions studied

  • Non-metastatic Prostate Cancer

Browse trials for

Keywords

  • androgen antagonists
  • prostate neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prostate cancer in the early stage of disease
  • Prostate removed and/or radiation therapy to the prostate area

Exclusion criteria

Exclusion Criteria:

  • Previous systemic therapy for prostate cancer
  • Previous history of another form of cancer (not prostate) within 5 years of study start.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3,618 participants (actual)

Study arms

  • Experimental
    1

    Drug: Bicalutamide

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • 150mg daily

    Also known as: Casodex™

  • DrugPlacebo

    once daily

06

What researchers measure

Primary outcomes

  1. Time to clinical progression

    Time frame: Throughout study period

  2. Overall patient survival

    Time frame: Throughout study period

Secondary outcomes

  1. Time to treatment failure

    Time frame: Throughout study period

  2. Serum prostate-specific antigen

    Time frame: Initial study period up to 2006 amended protocol

  3. Tolerability in terms of adverse events and laboratory parameters

    Time frame: Throughout study period

07

Study locations

85 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Scottsdale, Arizona, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Berkeley, California, United States
  • Research Site
    Laguna Woods, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Santa Monica, California, United States
  • Research Site
    Thousand Oaks, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Van Nuys, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Middlebury, Connecticut, United States
  • Research Site
    New Haven, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Aventura, Florida, United States
  • Research Site
    Bay Pines, Florida, United States
  • Research Site
    Boca Raton, Florida, United States
  • Research Site
    Daytona Beach, Florida, United States
  • Research Site
    Fort Myers, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    St. Augustine, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Fort Wayne, Indiana, United States
  • Research Site
    Greenwood, Indiana, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Kansas City, Kansas, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Greenbelt, Maryland, United States
  • Research Site
    Rockville, Maryland, United States
  • Research Site
    Burlington, Massachusetts, United States
  • Research Site
    Newtown, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    Hattiesburg, Mississippi, United States
  • Research Site
    Jackson, Mississippi, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Lebanon, New Hampshire, United States
  • Research Site
    Albany, New York, United States
  • Research Site
    Bronx, New York, United States
  • Research Site
    Manhasset, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Rochester, New York, United States
  • Research Site
    Syracuse, New York, United States
  • Research Site
    Asheville, North Carolina, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Lancaster, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Cordova, Tennessee, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Salt Lake City, Utah, United States
  • Research Site
    Danville, Virginia, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Virginia Beach, Virginia, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Madison, Wisconsin, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Cheyenne, Wyoming, United States
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Victoria, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Oakville, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Quebec, Canada
08

References and documents

Publications

  • Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x. PubMed 22129214 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1995, a primary completion of Jul 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2008
First posted
Apr 14, 2008
Start
Aug 1995
Primary completionActual
Jul 2008
CompletionActual
Aug 2008
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00657904
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 14, 2008
Start date
Aug 1995
Primary completion
Jul 2008
Completion
Aug 2008
Last update
Jun 6, 2012

Study contacts

William See
principal investigator · Medical College of Wisconsin
David G. McLeod
principal investigator · Walter Reed Army Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion